UPDATE: Voyager Therapeutics (VYGR) PT Raised to $37 at Nomura (Correction in Investment Bank Name)

(Updated to correct investment bank name - previously announced Mizuho Securities, but instead Nomura was the bank changing the target price)

Nomura analyst Christopher Marai raised the price target on Voyager Therapeutics (NASDAQ: VYGR) to $37.00 (from $26.00) while maintaining a Buy rating.

Analyst says: "VYGR announced a restructured deal with Sanofi: VYGR now has WW rights to VY-HTT01 for Huntington’s disease, and the ex-U.S. rights to VYFXN01 for Friedreich’s ataxia have now been transferred to NBIX. SNY has option rights to novel AAV capsids for up to two non-CNS indications. VYGR will pay SNY $10mn, but receive $5mn from NBIX. We increase our target price to $37 from $26, adjusting for the transaction, but note that VYGR is nearing a ″local maximum″ in terms of valuation, in our view; however, we see continued upside potential over the next 12 months."

You May Also Be Interested In

• Citi cuts Lowe's price target to $260, keeps Buy rating
• Lowe's (LOW) PT Lowered to $250 at Mizuho
• BofA Securities Upgrades Etsy (ETSY) to Buy, 'Still Room to Run'